Erythropoietin (EPO) vs LGD-4033
Extensively Studied vs Moderate Research
monitor Mechanism-based · 51% Both Erythropoietin (EPO) and LGD-4033 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Erythropoietin (EPO) LGD-4033
Weight 30,400 Da 338.25 Da
Half-life 4-12 hours (IV), ~25 hours (SubQ) ~24-36 hours
Chain 165 amino acids —
Type Glycoprotein hormone Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
Erythropoietin (EPO)
01 Stimulates red blood cell production
02 Increases oxygen-carrying capacity
03 FDA-approved for anemia treatment
04 Improves endurance capacity
05 Supports patients with chronic kidney disease
06 Helps chemotherapy-induced anemia
07 Well-characterized mechanism of action
08 Extensively studied safety profile
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Dosing Protocols
Erythropoietin (EPO)
50-300 IU/kg based on medical indication / 1-3 times weekly depending on response
CKD Anemia (medical) 50-100 IU/kg 3x weekly
Chemotherapy Anemia (medical) 150-300 IU/kg 3x weekly
Maintenance (medical) Individualized 1-3x weekly
LGD-4033
5-10 mg/day / Once daily (oral)
Side Effects
Erythropoietin (EPO)
Injection site reactions
Headache
Hypertension
Joint pain
Flu-like symptoms
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Uncontrolled hypertension
Pure red cell aplasia history
Hemoglobin >12 g/dL (increased cardiovascular risk)
Active malignancy (relative contraindication)
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
Erythropoietin (EPO) LGD-4033
Status Extensively Studied Moderate Research
References 4 studies 5 studies
Latest — 2018
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.